Targeting Important Pathways in Gastric Cancer: Focus on VEGFR2

Speaker: Florian Lordick

Discussion Points

  • Topline results of the RAINBOW trial: What is the clinical importance of the study findings?
  • Focus on ramucirumab: Class, mechanism of action, side-effects
  • How is VEGFR2 acting as a mediator of the majority of downstream effects of the VEGF pathway in Angiogenesis?

Abstracts discussed